Adaptive Biotechnologies rises after quarterly sales beat
View all comments(0)
Medical device maker Adaptive Biotechnologies Corp's ADPT.O shares rise as much as 34.5% to over a year high of $9.9
Stock is set for its best day since its IPO in 2019, if gains hold
Late on Thursday, ADPT posted 25% rise in Q1 revenue to $52.44 million, beating analysts' estimates of $42.68 million
Co reported Q1 net loss of $29.8 million, compared to $47.5 million for the same period in 2024
Co reported cash, cash equivalents and marketable securities of $232.8 million as of March 31, 2025
Co expects full year total company cash burn to be between $50 million and $60 million, from the previous range between $60 million and $70 million
As of last close, ADPT has fallen 62.1% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.